Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

An Interview With Franco Negron
Simtra’s capability to support high-volume injectables and lower-volume modalities provides balanced expertise across the sterile injectables landscape. read more
Leveraging AI and ML to Optimize Drug Discovery – a CRO Perspective
CROs supporting early-stage drug discovery projects are establishing their own internal AI platforms to address their clients’ needs in an evolving field. read more
Horizon Lines: A Quarterly Review of NDAs – January-March, 2026
The NDAs approved during the first quarter of 2026 have been divided into the dosage forms Injection, Tablets, Capsules, Oral solution, Gas, and other. read more
An Interview With Dave Miller, Ph.D.
Early formulation decisions can make or break a program, yet they’re often made under significant data constraints. What are the most common mistakes sponsors make when they rush that decision, and what does it typically cost them downstream? read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Genezen, Galibra Partner on SSADH Gene Therapy
Thursday, October 15, 2026
Genezen and Galibra Neuroscience have entered a manufacturing partnership to prepare Galibra’s experimental gene therapy for succinic semialdehyde ... read more
Charles River, Magellan Partner on Zelestrocel Testing
Thursday, October 15, 2026
Charles River Laboratories has agreed to provide testing and development services to Magellan Stem Cells as the Australian biotechnology company ... read more
Perceptive, Nucleus Form Radiopharmaceutical Partnership
Thursday, October 15, 2026
Perceptive Discovery and Nucleus RadioPharma have formed a nonexclusive partnership linking preclinical testing with clinical manufacturing for ... read more
Lonza Expands Six-Month Biologics Development Offering
Thursday, October 15, 2026
Lonza has expanded its development and manufacturing offering to include more complex biologic medicines, with a stated goal of preparing some ... read more
Lonza Licenses Qurient Technology for Dual-Payload ADCs
Tuesday, October 13, 2026
Lonza has signed an exclusive license agreement with Qurient to use the Korean biotechnology company’s cyclin-dependent kinase 7 inhibitors in dual-... read more